In order to further verify the accuracy of our model construction, we built a prognostic risk model in the target database, and further tested that low expression of PARM1 indicates poor prognosis of osteosarcoma patients, which further verified the accuracy of our model. This evidence concerns the gene PARM1 and osteosarcoma.